Epstein-Barr virus, rapamycin, and host immune responses

Current Opinion in Organ Transplantation

Volumn 13, Issue 6, 2008, Pages 563-568

  Krams, Sheri M ^a   Martinez, Olivia M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell lymphoma; Epstein Barr virus; Posttransplant lymphoproliferative disease; Rapamycin

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RAPAMYCIN; STEROID; TEMSIROLIMUS; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE;

B CELL LYMPHOMA; CARDIAC ALLOGRAFT VASCULOPATHY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOGENETICS; DRUG MECHANISM; EPSTEIN BARR VIRUS; GENOMICS; GRAFT RECIPIENT; GRAFT REJECTION; HERPES VIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MEMORY T LYMPHOCYTE; NONHUMAN; POSTOPERATIVE INFECTION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; REVIEW; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS; ANIMAL; DRUG EFFECT; GRAFT SURVIVAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; ORGAN TRANSPLANTATION; PATHOGENICITY; REGULATORY T LYMPHOCYTE; VIROLOGY; VIRUS INFECTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; T-LYMPHOCYTES, REGULATORY;

EID: 60849100558     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283186ba9     Document Type: Review

References (43)

1. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36:69-86.
2. Craig FE, Johnson LR, Harvey SA, et al. Gene expression profiling of EpsteinBarr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn Mol Pathol 2007; 16:158-168.
3. Vakiani E, Basso K, Klein U, et al. Genetic and phenotypic analysis of B-cell posttransplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol 2008 [Epub ahead of print].
4. Vakiani E, Nandula SV, Subramaniyam S, et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol 2007; 38:315-325.
5. Alsayed Y, Leleu X, Leontovich A, et al. Proteomics analysis in post transplant lymphoproliferative disorders (PTLD). Eur J Haematol 2008 [Epub ahead of print].
6. Falco DA, Nepomuceno RR, Krams SM, et al. Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 2002; 74:501-510.
7. Macedo C, Donnenberg A, Popescu I, et al. EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transpl Immunol 2005; 14:109-116.
8. Melkus MW, Estes JD, Padgett-Thomas A, et al. Humanized mice mount specific adaptive and innate immune responses to EBVandTSST-1. Nat Med 2006; 12:1316-1322.
9. Lim WH, Kireta S, Russ GR, Coates PT. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood 2007; 109: 1043-1050.
10. GuppyAE, RawlingsE, Madrigal JA, et al. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation 2007; 84:1534-1539.
11. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003; 170:6183-6189.
12. Popescu I, Macedo C, Abu-Elmagd K, et al. EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells. Am J Transplant 2007; 7:1215-1223.
13. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-687.
14. Snow AL, Martinez OM. Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7:271-277.
15. Pfeffer S, Zavolan M, Grasser FA, et al. Identification of virus-encoded microRNAs. Science 2004; 304:734-736.
16. Xia T, O'Hara A, Araujo I, et al. EBV microRNAs in primary lymphomas and targeting of CXC-11 by ebv-mir-BHRF1-3. Cancer Res 2008; 68:1436-1442.
17. Motsch N, Pfuhl T, Mrazek J, et al. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol 2007; 4:131-137.
18. Snow AL, Lambert SL, Natkunam Y, et al. EBV can protect latently infected b cell lymphomas from death receptor-induced apoptosis. J Immunol 2006; 177:3283-3293.
19. Hislop AD, Ressing ME, van Leeuwen D, et al. ACD8+Tcell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 2007; 204:1863-1873.
20. Rowe M, Glaunsinger B, van Leeuwen D, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA 2007; 104:3366-3371.
21. Zuo J, Thomas W, van Leeuwen D, et al. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+T cells through an additional host shutoff function. J Virol 2008; 82:2385-2393.
22. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
23. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63:917-926.
24. Stallone G, Schena A, Infante B, et al. Sirolimusfor Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-1323.
25. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97:4285-4290.
26. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63:4472-4480.
27. Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007; 179:8225-8234.
28. Vaysberg M, Balatoni CE, Nepomuceno RR, et al. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 2007; 83:1114-1121.
29. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls FoxP3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008; 105:7797-7802.
30. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+FoxP3+ cells. J Exp Med 2008; 205:565-574.
31. El-Salem M, Raghunath PN, Marzec M, et al. Constitutive activation of mTOR signaling pathway in posttransplant lymphoproliferative disorders. Lab Invest 2007; 87:29-39.
32. MathewT, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446-449.
33. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80:749-758.
34. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581-589.
35. KirkAD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7:2619-2625.
36. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8:984-989.
37. Caillard S, DharnidharkaV, AgodoaL, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80:1233-1243.
38. Iaria G, Anselmo A, De Luca L, et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports. Transplant Proc 2007; 39:2036-2037.
39. Pascual J. Posttransplant lymphoproliferative disorder: the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22 (Suppl 1): i27-i35.
40. Cullis B, D'Souza R, McCullagh P, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47:e67-e72.
41. Boratynska M, Watorek E, Smolska D, et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007; 39:2736-2739.
42. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-858.
43. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-5356.